iBio, Inc. (MUN:0JV0) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants in lieu thereof) Announced: about US$26M · US$2.35 a share · Leerink Partners +2 Dealers: Leerink Partners (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead) Buyers: Frazier Life Sciences Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610, IBIO-600 and bispecifics, other pipeline assets, working capital and general corporate purposes | Jan 9, 2026 |
| Public offering of pre-funded warrants and accompanying Series G warrants Closed: US$50M raised · US$0.699 a share · ½ warrant at US$0.7 · Leerink Partners +3 Dealers: Leerink Partners (lead), LifeSci Capital, Oppenheimer & Co., Brookline Capital Markets Buyers: Balyasny Asset Management; Cormorant Asset Management; Adage Capital Partners LP; Ally Bridge Group; Marshall Wace; Coastlands Capital; SilverArc Capital Management; Vestal Point Capital; Ausangate Capital Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610 and IBIO-600, other pipeline assets, working capital and general corporate purposes | Aug 25, 2025 |
| Warrant exercise of shares of common stock upon exercise of existing warrants Announced: about US$6.2M · US$1.11 a share · Warrants at US$0.86 for 60 months · Chardan Dealers: Chardan Use of proceeds: Working capital and other general corporate purposes | Apr 29, 2025 |
| Private placement of private placement offering Closed: US$650,000 raised Insiders: Private placement with members of its Board of Directors and Officers | Jan 13, 2025 |